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A B S T R A C T
The triple therapy of Helicobacter pylori eradication prevents repeated bleeding from stomach ulcer. The aim of this
one-way blind prospective study was to evaluate the efficiency of the two-week triple therapy for Helicobacter pylori
eradication in preventing renewed bleeding in patients with stomach ulcer within one year. This research included 60
hospitalized patients with bleeding stomach ulcer and positive Helicobacter pylori infection, 34 men and 26 women
(average age 59.7 years). The patients were given therapeutic scheme of omeprazol – amoxicilin – metrodinazol (OAM)
eradication for 14 days. Eradication of H. pylori infection was defined as lack of proof of the infection one month or sev-
eral months after therapy suspension. By applying triple OAM therapy within two weeks the eradication was success-
ful in 72%. In the group of 17 H. pylori positive patients there were 8 patients (47.6%) with repeated stomach ulcer and
3 patients (18%) with bleeding. Within the group of 43 H. pylori negative patients there were only 2 patients (4.65%)
with repeated stomach ulcer and 1 patient (2%) with bleeding, during the observed period of 12 months. This research
confirms the hypothesis about the necessity of eradication of Helicobacter pylori infection in patients with bleeding
stomach ulcer as prevention of repeated bleeding.
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Introduction
Helicobacter pylori colonizes surface of the stomach
mucous membrane and is one of the most important
etiologic factors, which cause the chronic gastritis B and
ulcer disease. It has been identified as first class carcin-
ogen according to World Health Organization because of
being involved with the development of adenocarcinoma
of stomach and MALT lymphoma.
Prevalence of H. pylori infection in bleeding from du-
odenal ulcer is 97% and in bleeding from stomach ulcer
84%1. Before the role of H. pylori in the pathogenesis of
ulcer disease has been recognized, patients were usually
given half the doses of the H2 blockers maintaining ther-
apy after the first episode of bleeding. Research of the
half doses of maintaining therapy with H2 blocker at
night showed great reduce of recidivism of duodenal ul-
cer for 20–25%, in distinction from placebo where 60–
90% of recidivism has been traced. The recidivism of
gastric ulcer and its response to half of the maintaining
therapy H2 blocker at night is similar to duodenal ulcer.
The annual recidivism of gastric ulcer on the maintain-
ing therapy is reduced to 10–30% in distinction from
placebo where there is recidivism between 30 and 80%2,3.
According to the already mentioned Spanish study1,
H. pylori eradication therapy is a choice therapy in pre-
venting of recidivism of bleeding duodenal ulcer. During
12 months of research there was no trace of any recidi-
vism of bleeding without giving the maintaining anti-
secretory therapy. After the successful eradication of H.
pylori the annual recidivism of bleeding peptic ulcer is
between 0–3%. During 24 months of observation there
was not traced a single ulcer or ulcer bleeding recidi-
vism after the given therapy without the maintaining
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H2 blocker therapy3. Gastric ulcer recidivism has been
traced after the successful eradication of H. pylori only
with 2.3% of patients in the period of one year4. There is
better efficiency in preventing duodenal bleeding with
dual eradication therapy by antibiotics and PPI, rather
than PPI and H2 blocker in monotherapy). In the period
of 27 months it has not been traced any recidivism
bleeding from duodenal or gastric ulcer after success-
fully applied triple or quadruple eradication therapy of
H. pylori6.
So we came to the question whether to prevent and
postpone the recidivism of ulcer bleeding by expensive
and long lasting maintaining therapy with H2 blocker or
to make eradication of H. pylori with the following
blocker treatment of proton pump without maintaining
therapy or to combine both.
Materials and methods
60 hospitalized patients with bleeding stomach ulcer
and combined H. pylori infection were involved in this
research. The existence of stomach ulcer and accompa-
nying bleeding was found through endoscopy and pres-
ence of H. pylori infection through bioptic ureasis test
and histology. The bleeding was stopped endoscopically,
by injection sclerosant technique with 1% Polidocanol.
The patients were acquainted with the medicines they
were given. After 14 days of treatment 4–6 biopsies
were taken from the edge of the ulcer to eliminate the
malignancy. Patients with difficult respiratory, cardio-
vascular, renal or liver diseases, patients on long lasting
drug therapies (especially nonsteroid antireumatics),
psychiatric patients, pregnant and breastfeeding wo-
men and patients with already operated abdomen were
not involved in this research.
The bleedings were categorized according to For-
rest's classification. The patients were given, apart from
endoscopic homeostasis and antishock therapy, raniti-
dine 4 x 100 mg i.v. during three to four days depending
on stopping of bleeding and transition to peroral feed-
ing. After transition to peroral therapy the patients
were given omeprazol 40 mg in the morning before tak-
ing meal.
After the infection had been confirmed the eradica-
tion was done with omeprazol 40 mg in the morning be-
fore taking meal, with amoxicilin 2 x 1000 mg during 14
days and metronidazol 3 x 500 mg also during 14 days.
After this therapy, the patients were given omeprazol 20
mg in the morning before meal until the ulcer was im-
proved (healed). The control endoscopic examinations
were done 1, 6 and 12 months after the ulcer was im-
proved (healed) or after the symptoms had occurred.
None of the patients was given the maintaining therapy.
Eradication of H. pylori infection was defined as lack
of proof through bioptic urease test and histology one
month or several months after the therapy has been
stopped.
Endoscopes (Olympus GIF Q10) and bioptic forceps
(Olympus FB 24K) were sterilized with 2% glutaralde-
hid between the examinations. Four bioptic samples
were taken (2 from stomach antrum within 4 cm from
pylorus and 2 from stomach corpus), 2 samples for his-
tology and 2 samples for urease test.
The statistic analysis was made by t-test propotions
where:
(t) = Sqrt(N1+N2(N1+N2)*p1–p2/Sqrt (p*q)
p = (pl*n1+p2*n2) (N1+N2), q=1–p.
Results
60 patients with bleeding stomach ulcer and positive
H. pylori infection were involved in this research. It
could be seen in Table 1 that the average age of patients
was 59.7 years. During the first endoscopic examination
and sclerosation, the biggest percentage of patients
(56.66%) was in the second group of Forrest's classifica-
tion of bleeding activities, 31.66% in the IB group and
11.66% in IA group (Table 2).
After H. pylori status has been determined and eradi-
cation therapy given, endoscopic examination was per-
formed in intervals of 1, 6 or 12 months during the pe-
riod from the beginning of 1998 till the end of 2000. The
period was lengthened because some new patients were
involved. It was not possible to make contacts with some
of the patients for the necessary examination.
The eradication through triple therapy with omepra-
zol 40 mg in the morning before taking the meal, amo-
xicilin 2 x 1000 mg a day and metrodinazol 3 x 500 mg
during 14 days (OAM) was 72% successful.
During 12 months of this research 8 ulcer recidives
(out of 17 patients with H. pylori infection) were identi-
fied, and 2 out of 43 patients with successful eradication
H. pylori (Table 3). The repeated bleeding was traced in
3 out of 17 patients with H. pylori infection, and only in
1 out of 43 patients with negative H. pylori status. There
is a significant statistical difference in ulcer recidivism
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TABLE 1
CHARACTERISTICS OF THE PATIENTS WITH THE
BLEEDING STOMAC ULCER
Number of patients 60
Proportion men:women 32:26
Average age in years 59.7
TABLE 2
PERCENTAGE OF THE PATIENTS IN GROUPS ACCORDING TO
THE FORREST'S CLASSIFICATION OF BLEEDING ACTIVITIES
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between the patients with positive and negative H.
pylori status (p<0.001) (Table 4). There is also great sta-
tistical difference in renewed bleeding between the
group with positive and negative H. pylori status during
12 months of observation (p=0.03).
Discussion
The real history of the peptic ulcer of patients who
were not operated was settled down in 50th and 60th
years of the previous century. Renewed bleeding was
traced in 19.5–46% of the patients with one previous
bleeding and in 23.5–62% of the patients with two previ-
ous bleedings. Besides this tendency of bigger bleeding,
the risk is not lessened by continuous observation. The
more update research shows that 13–16% of the pa-
tients with one previous bleeding will bleed once again
with the average observation within 3–8 years, and 35%
of the patients with two previous bleedings will bleed
again9–11. Surgery could lessen the percentage of recidi-
vism and percentage of following complications of ulcer
disease, but at stake of acute and chronically morbidity.
That is why it has been looked for nonsurgical alterna-
tives in long-lasting therapy of ulcer with bleeding com-
plications. The possibility of therapy with H2 antago-
nist occurred in order to lessen the percentage of re-
newed ulcer bleeding12–14. This therapy must be given
once a day, because the ulcer recidivism comes back to
placebo effects if the therapy is intermittent or stopped.
During three years of observation, Penston and Worm-
sley13 have retrospectively found bleeding from ulcer in
1.3% of the patients on long-term maintaining therapy
with antagonist to H2 receptors, in comparison to 15.2%
of those on placebo In the second multicentral, random
and control study with 65 patients with endoscopically
confirmed bleeding from the duodenal ulcer, the re-
newed bleeding was traced in 3 out of 32 (9.3%) patients
who were given ranitidine, unlike 12 out of 33 (36.4%)
patients who were given placebo12. The disadvantages
of longterm maintaining therapy with H2 receptors
blockers include high price, need for the longterm coop-
eration, possible side–effects and interaction with other
medications.
Based on great number of research, which proved
that eradication H. pylori infection lessens the percent-
age of ulcer recidivum15–20, it is supposed that the num-
ber of ulcer complications will lessen. The previous work
of Graham from 1993, Labenz from 1994, Jaspersen and
Rokkas from 1995 showed the benefit of the eradication
therapy for patients with bleeding duodenal and stom-
ach ulcer as bleeding prevention by patients who be-
came H. pylori negative through the certain period of
observation21–24. The same facts could be found in more
recent works1–6. It is difficult to compare these studies
with ours because there are different therapy eradica-
tion schemes and the patients included were with duo-
denal and stomach ulcer. However, it was important to
note the renewed bleeding in the group of H. pylori posi-
tive and negative patients. In distinction from our
study, the mentioned authors and co-workers had the
bigger percentage of eradication of H. pylori (80%),
whereas our research identified 72% of the patients
eradicated from H. pylori, what is probably due to resis-
tance to metronidazol therapy in our subpopulation.
One more possible reason for smaller eradication per-
centage is poor cooperation of patients during classical
triple 14 days OAM therapy, because older persons were
involved. Ulcer recidivism occurred within H. pylori po-
sitive group in 47% of the cases and in the H. pylori neg-
ative group in 4.6%, and there is not a big difference
when comparing to the already mentioned studies. Dur-
ing 12 months of observation the renewed bleeding was
traced in 18% within H. pylori positive patients and in
2% within H. pylori negative group. The already men-
tioned authors did not find any renewed bleeding within
the group of H. pylori negative patients during the pe-
riod of observation, and 19–46% within the H. pylori
positive group.
Our results confirm the hypothesis that H. pylori is
an integral part of the pathogenesis of ulcer disease and
its eradication results with prevention of renewed ulcer
thus ulcer complications, as well.
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TABLE 3
NUMBER AND PERCENTAGE OF THE PATIENTS WITH THE
RECIDIVISM OF STOMACH ULCER ACCORDING TO H. PILORY






Ulcer recidivum N (%) 8/17 (47.05%) 2/43 (4.6%)
TABLE 4
NUMBER AND PERCENTAGE OF THE PATIENTS WITH THE
RECIDIVISM OF BLEEDING FROM THE STOMACH ULCER






Bleeding recidivism N (%) 3/17 (18%) 1/43 (2%)
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UTJECAJ ERADIKACIJE INFEKCIJE S HELICOBACTER PYLORI NA RECIDIV
KRVARENJA KOD BOLESNIKA S @ELU^ANIM VRIJEDOM
S A @ E T A K
Trojna terapija eradikacije Helicobacter pylori prevenira recidiv krvarenja iz `elu~anog vrijeda. Cilj ove jedno-
struko slijepe prospektivne studije bio je evaluirati efikasnost trojne dvotjedne terapije eradikacije H. pylori u pre-
venciji ponovljenog krvarenja kod bolesnika s `elu~anim vrijedom, u trajanju od 1 godine. U ispitivanje je uklju~eno
60 hospitaliziranih bolesnika s krvare}im `elu~anim vrijedom i pozitivnom Helicobacter pylori infekcijom, 34 mu{-
karca i 26 `ena prosje~ne starosti 59,7 godina. Bolesnici su dobivali terapijsku shemu eradikacije omeprazol-amo-
ksicilin-metronidazol (OAM) kroz 14 dana. Eradikacija H. pylori infekcije definirala se kao nedostatak dokaza infek-
cije biopti~ki ureaza testom i histologijom, jedan ili vi{e mjeseci nakon prestanka davanja terapije. Primjenjenom
trojnom terapijom OAM kroz dva tjedna uspje{nost eradikacije je bila 72%. U grupi od 17 bolesnika koji su bili H.
pylori pozitivni, bilo je 8 bolesnika (47,06%) s recidivom `elu~anog ulkusa i 3 bolesnika (18%) s krvarenjem, a u grupi
od 43 bolesnika s negativnim H. pylori statusom samo 2 bolesnika (4,65%) s recidivom `elu~anog ulkusa samo 1
bolesnik (2%) s krvarenjem, tijekom pra}enja od 12 mjeseci. Ovo ispitivanje potvr|uje hipotezu o potrebi primjene
terapije eradikacije u bolesnika s krvare}im `elu~anim vrijedom u svrhu prevencije ponovljenog krvarenja.
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